Samantha Cimitan named new CEO at Celonic

3 August 2023

Switzerland-based biologics contract development and manufacturing organization (CDMO), Celonic Group has appointed Dr Samantha Cimitan as chief executive.

Dr Cimitan succeeds Dr Konstantin Matentzoglu, who will step down after nine years as CEO. During his tenure, he successfully repositioned the Celonic brand as a premium CDMO, delivered significant growth, and facilitated corporate development and strategic alliances. Dr Matentzoglu intends to remain a member of the Celonic board and will support Samanta during the transition.

With more than 20 years of experience working, teaching, and studying life sciences, Dr Cimitan is an expert in the CDMO industry, holding a deep and unique combination of scientific, commercial, and operational know-how.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK